AnaptysBio Inc (ANAB)
🔔 Watch stock
Stock Watch
Stock Watch will tell you what changes at AnaptysBio Inc.
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Appears in These Scanners
This stock currently matches 12 of our scanner strategies — each hit links to the scanner.
Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. View all scanners
Trading Day
Key levels of the most recently completed trading day — not a live quote.
52-Week Range
Current price 53.40 $ — 67% of the range above the low.
Lowest and highest closing price over the last 52 weeks. The marker shows where the current price sits within that range: close to the high speaks for strength, close to the low for weakness.
Basics
Performance
Technical Indicators
Calculated from the price history · as of 08/03/2026
Valuation
Profitability
Balance Sheet & Safety
Growth
Dividend
This stock currently pays no dividend.
Quality & Screener
AI Rating
–Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available. How the Rating Is Built
Growth Score
8 of 10 Growth gemTen checks against the annual reports — each one passed counts a point.
- Revenue grows by more than 15% a year over three years 183.5% passed
- More than 10% revenue growth is expected for the coming year 39.7% passed
- Share count grows by less than 3% a year 3.6% failed
- Revenue growth plus cash-flow margin add up to at least 40 ("Rule of 40") 165.4% passed
- Gross margin at 40% or higher and without meaningful erosion 99.0% passed
- Goodwill from acquisitions does not grow faster than revenue 0.0% passed
- Net debt below twice EBITDA 298 m net cash passed
- Operating cash flow covers the profits of the last three years 86 m passed
- Return on capital at 15% or higher, or up versus two years ago 14.7% passed
- Insiders hold at least 10% or are net buyers 5.8% failed
A criterion without figures counts neither as passed nor as failed; a score is only produced from 7 judgeable criteria upwards. Source: fundamental data. All ten criteria in detail
Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.
Analysts & Price Target
The price target sits 63.1% above the current price.
- Consensus
- Sell
- Analyst Ratings
- 12
Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.
Estimates by Fiscal Year
| Fiscal Year | EPS Estimate ($) | EPS Range ($) | Revenue Estimate ($M) | Expected Growth | Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | -0.23 | -2.63 – 2.49 | 94 | 49.8% | 5 |
| 12/31/2027 | 5.24 | 2.86 – 8.77 | 153 | 2,369.2% | 5 |
Average of the analyst estimates for the coming fiscal years. The range shows how far the most optimistic and the most cautious estimate sit apart — the wider it is, the less certain the expectation.
Next Reporting Date
- Expected Earnings per Share
- -0.22 $
Expected date of the next quarterly or annual figures. Dates do shift occasionally — only the invitation issued by the company is binding.
Revenue & Profit
Cash Flow
Balance Sheet
Margins
Per Share
Click the chart or tab into it, then use ← and → to step through the periods.
None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.
· Total · per year
These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.
The figures could not be loaded right now.
Source: fundamental data
Quarterly Figures
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | -0.72 | – | 43 | 378.80 | -50.50 | -67 | -67 |
| 2025: Q1 | -1.28 | – | 28 | 286.80 | -141.60 | -11 | -11 |
| 2025: Q2 | -1.34 | – | 22 | 102.90 | -173.50 | -40 | -40 |
| 2025: Q3 | 0.52 | – | 76 | 154.30 | 19.80 | -27 | -27 |
| 2025: Q4 | 1.58 | – | 108 | 151.10 | 45.80 | 98 | 98 |
| 2026: Q1 | -1.84 | – | 26 | -8.00 | -206.90 | -26 | -26 |
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
Annual Figures
| Fiscal Year | Revenue ($M) | EBIT ($M) | Net Income ($M) | EPS ($) | Operating Cash Flow ($M) | Equity ($M) | Total Assets ($M) |
|---|---|---|---|---|---|---|---|
| 2016 | 17 | -3 | -4 | -1.62 | -9 | 39 | 62 |
| 2017 | 10 | -29 | -30 | -1.52 | -19 | 308 | 329 |
| 2018 | 5 | -67 | -62 | -2.50 | -49 | 486 | 509 |
| 2019 | 8 | -107 | -97 | -3.60 | -70 | 405 | 435 |
| 2020 | 75 | -24 | -20 | -0.73 | -14 | 397 | 417 |
| 2021 | 63 | -57 | -58 | -2.11 | -46 | 356 | 643 |
| 2022 | 10 | -115 | -129 | -4.57 | -74 | 262 | 610 |
| 2023 | 17 | -164 | -164 | -6.08 | -121 | 88 | 452 |
| 2024 | 91 | -115 | -145 | -5.12 | -135 | 71 | 484 |
| 2025 | 235 | 48 | -13 | -0.42 | 20 | 37 | 364 |
Fiscal years from the audited annual reports, oldest first. EBIT is the operating profit before interest and taxes; total assets are everything the company owns.
About the Company
AnaptysBio, Inc., ein Biotechnologieunternehmen im klinischen Stadium, konzentriert sich auf die Bereitstellung immunologischer Therapeutika für Autoimmun- und entzündliche Erkrankungen in den USA.
| CEO Insider Trades (12 Mo.) | selling own stock |
|---|---|
| Employees | 104 |
| Headquarters | San Diego, CA |
| Address | 10770 Wateridge Circle, 92121-5801 San Diego, United States |
| Phone | 858 362 6295 |
| Website | anaptysbio.com |
| IPO Date | 26. Jan 2017 |
| ISIN | US0327241065 |
| Stock Split | 15:10 on 04/20/2026 |
Management
| Name | Title | Birth Year |
|---|---|---|
| Daniel R. Faga | President, CEO & Director | 1980 |
| Christopher M. Murphy | Chief Financial Officer | 1984 |
| Beth Mueller | Senior Vice President of Human Resources | – |
| Martin Dahl Ph.D. | Senior Vice President of Research | – |
| Benjamin Stone | Chief Business Officer | 1991 |
| Monique Da Silva | Senior Vice President of Corporate Affairs | – |
| Priya Raina | Senior Vice President of Clinical Operations | – |
| Cailin Sibley FACR, M.D. | Senior Vice President of Translational Medicine | – |
| John Kwon | Vice President of GI Clinical Development | – |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Chart
Interactive price chart (TradingView).
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.